The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer
- 97 Downloads
To the editor
The maintenance of skeletal integrity in a healthy individual requires a balanced bone remodeling. Osteoclast-mediated bone resorption is a common factor in the pathogenesis of osteoporosis and metastatic bone disease [3, 4]. Evidence is given, that tumor mediated osteoclast activation disrupts the normal equilibrium of bone remodeling, allowing tumor cells to survive and grow in this microenvironment [4, 5].
A functional dimorphism, 13910 C/T (LCT) which is associated with adult lactose intolerance, has been suggested as a possible risk factor for osteoporosis and bone fractures, particularly in postmenopausal women .
In the present study, we investigated the impact of the 13910 C/T LCT polymorphism on the risk of bone metastasis in 500 breast cancer patients. Patient characteristics have been described previously . The study was...
KeywordsBreast Cancer Osteoporosis Bone Metastasis Lactose Intolerance Metastatic Bone Disease
The genotyping of LCT was financed by the Province of styria, Department of Science & Research, Transport & Technology. Special thanks to Mrs. Nicole Prutsch and Dr. Birgit Strimitzer-Riedler who heavily supported our project.
- 2.Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev Sep 5 [Epub ahead of print]Google Scholar
- 6.Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W (2004) Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Miner Res 19(1):42–47PubMedCrossRefGoogle Scholar
- 8.de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J (2001) Probiotics—compensation for lactase insufficiency. Am J Clin Nutr 73(2 Suppl):421–429Google Scholar
- 10.Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Asil Y, Gluer CC, Schrezenmeir J (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137(3 Suppl 2):838–846Google Scholar
- 11.Obermayer-Pietsch BM, Gugatschka M, Reitter S, Plank W, Strele A, Walter D, Bonelli C, Goessler W, Dobnig H, Högenauer C, Renner W, Fahrleitner-Pammer A (2007) Adult-type hypolactasia and calcium availability: decreased calcium intake or impaired calcium absorption? Osteoporos Int 18(4):445–451PubMedCrossRefGoogle Scholar
- 14.Roodman GD (2004) Mechanisms of bone metastasis, Review. N Engl J Med 15; 350(16):1655–1664Google Scholar
- 15.Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2007 May 2 [Epub ahead of print]Google Scholar
- 16.Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow—a longtime follow-up. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 529Google Scholar
- 17.Powles T, McCloskey E, Kurkilahti M (2004) Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 528Google Scholar
- 18.Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 527Google Scholar
- 20.McClung MR, Lewiecki EM, Cohen SB et al (2006) AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821–831Google Scholar
- 21.Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 2007 Nov 4 [Epub ahead of print] Google Scholar